Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 96

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 96
---
ITEM 1.    FINANCIAL STATEMENTS

Denali Therapeutics Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share amounts)

March 31, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$56,947 $174,960 Short-term marketable securities760,979 657,371 Prepaid expenses and other current assets60,712 32,105 Total current assets878,638 864,436 Long-term marketable securities235,844 359,373 Property and equipment, net57,765 55,236 Finance lease right-of-use asset50,199 47,533 Operating lease right-of-use asset21,963 22,861 Other non-current assets26,934 24,741 Total assets$1,271,343 $1,374,180 Liabilities and stockholders' equity Current liabilities:Accounts payable$8,458 $11,137 Accrued compensation7,655 24,728 Accrued clinical and other research and development costs27,908 22,822 Accrued manufacturing costs14,579 12,779 Operating lease liability, current8,585 8,308 Deferred research and development funding liability, current17,338 14,129 Other accrued costs and current liabilities7,354 8,305 Total current liabilities91,877 102,208 Operating lease liability, less current portion34,449 36,673 Finance lease liability, less current portion5,598 5,615 Deferred research funding and development liability, less current portion16,733 — Total liabilities148,657 144,496 Commitments and contingencies (Note 6)Stockholders' equity:Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024— — Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 145,251,258 shares and 144,220,986 shares issued and outstanding as of March 31, 2025 and December 31,